Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 18/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.79 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.79 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.71 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.71 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6390452 | 1.00 | ADORA1 (0.79) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL7787928 | 0.92 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL7785896 | 0.92 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL6391957 | 0.92 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL6394360 | 0.92 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL6393659 | 0.92 | ADORA1 (0.81) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL6389328 | 0.91 | ADORA1 (0.73) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL6398040 | 0.91 | ADORA1 (0.78) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL7789572 | 0.91 | ADORA1 (0.78) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL6396219 | 0.91 | ADORA1 (0.75) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010008883-A1 | Method of identifying partial adenosine A1 receptor agonists and their use in the treatment of arrhythmias | CV THERAPEUTICS, INC. | 2001-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008883-A1 | Method of identifying partial adenosine A1 receptor agonists and their use in the treatment of arrhythmias | ADORA1, ADORA3, ADORA2A | ADORA1 1/4885ADORA3 2/4885ADORA2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.